Real-world Treatment Patterns and Reasons for Therapy Selection in Patients with Advanced Hepatocellular Carcinoma in US Oncology Practices

BACKGROUND: The treatment landscape for advanced hepatocellular carcinoma (aHCC) is rapidly expanding beyond tyrosine kinase inhibitors (TKIs) in the first-line (1L) setting, with multiple TKIs and immune-checkpoint inhibitors (ICIs) now being evaluated in combination. Real-world evidence describing...

Descripción completa

Detalles Bibliográficos
Autores principales: Klink, Andrew J, Marshall, Landon Z, Aly, Abdalla, Seal, Brian, Healey, Marcus J, Feinberg, Bruce
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Hepatobiliary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8914483/
https://www.ncbi.nlm.nih.gov/pubmed/35274709
http://dx.doi.org/10.1093/oncolo/oyab059

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8914483/
https://www.ncbi.nlm.nih.gov/pubmed/35274709
http://dx.doi.org/10.1093/oncolo/oyab059

Ejemplares similares